21 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced draft guidance that would expand transparency and disclosure when the agency grants a conflict of interest waiver to permit an individual's participation at an

FDA advisory committee meeting.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The draft guidance would expand the information disclosed about waivers prior to committee meetings. Specifically, the FDA proposes to post online the name of the company or institution associated with the financial interest along with the type of conflict of interest.

Scientific advisory committees provide expert advice on significant scientific, technical, and policy matters to assist in the FDA's mission to protect and promote the public health. The committees provide advice on specific regulatory decisions, such as product approvals, and general policy matters, including regulations and guidance.

At times, the FDA believes it is appropriate to seek advice from experts who are top authorities in specific areas and who may have conflicts of interest.

"In my view, it is clearly better for the agency in fulfilling its public health mission when advisors have no conflicts of interest," FDA Commissioner Margaret A. Hamburg, M.D. said in a letter to senior agency officials concerning the proposed guidance. "FDA staff should search far and wide for experts who have the requisite knowledge without conflicts of interest. At the same time, however, I recognize the fact that many of the top authorities in specific areas may have conflicts of interest."

In her letter, Hamburg listed three steps, consistent with existing agency policy, to minimize concerns when needed experts may have a conflict of interest

Consideration of the nature of the conflict of interest, recognizing that not all conflicts are created equal. For example, an academic researcher whose institution receives grants from an affected company but who does not personally participate in the studies has a more tangential relationship to the conflict than the researcher who conducts studies for the company directly.

Consideration of the type of advice to be provided by the advisory committee. A waiver may be more appropriate for a meeting about a policy issue affecting a class of entities or products than for a meeting focusing on approval of a specific product.

Justification of waiver recommendations with a description of the search for equally expert advisors without conflicts and an explanation of why the individual's participation is needed to afford the advisory committee essential expertise.

Your comments are automatically posted once they are submitted. All comments are however constantly reviewed for spam and irrelevant material (such as product or personal advertisements, email addresses, telephone numbers and website address). Such insertions do not conform to our policy and 'Terms of Use' and are either deleted or edited and republished.Please keep your comments brief and relevant.This section may also have questions seeking help. If you have the information you are welcome to respond, but please ensure that the information so provided is genuine and not misleading.

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.Full Disclaimer